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Abstract
Objective Finasteride reduces prostate cancer risk by
blocking the conversion of testosterone to dihydrotestos-
terone. However, whether ﬁnasteride affects estrogens
levels or change in estrogens affects prostate cancer risk is
unknown.
Methods These questions were investigated in a case–
control study nested within the prostate cancer prevention
trial (PCPT) with 1,798 biopsy-proven prostate cancer
cases and 1,798 matched controls.
Results Among men on placebo, no relationship of serum
estrogens with risk of prostate cancer was found. Among
those on ﬁnasteride, those in the highest quartile of base-
line estrogen levels had a moderately increased risk of
Gleason score\7 prostate cancer (for estrone, odds ratio
[OR] = 1.51, 95% conﬁdence interval [CI] = 1.06–2.15;
for estradiol, OR = 1.50, 95% CI = 1.03–2.18). Finaste-
ride treatment increased serum estrogen concentrations;
however, these changes were not associated with prostate
cancer risk.
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DOI 10.1007/s10552-011-9787-7Conclusion Our ﬁndings conﬁrm those from previous
studies that there are no associations of serum estrogen
with prostate cancer risk in untreated men. In addition,
ﬁnasteride results in a modest increase in serum estrogen
levels, which are not related to prostate cancer risk. Whe-
ther ﬁnasteride is less effective in men with high serum
estrogens, or ﬁnasteride interacts with estrogen to increase
cancer risk, is uncertain and warrants further investigation.
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Introduction
Prostate cancer is the most common non-skin malignancy
among men in the United States, with an estimated 217,730
incident cases and 32,050 deaths in 2010 [1]. Relatively
few etiologic factors for prostate cancer have been con-
clusively identiﬁed. The difﬁculty in identiﬁcation of these
risk factors may be best illustrated by studies on the rela-
tionship between sex steroid hormones and prostate cancer
risk. Prostate cancer is generally deemed androgen-related,
and almost always responds initially to androgen-depriva-
tion therapy [2]. However, numerous epidemiologic studies
on circulating androgen levels and prostate cancer risk
have been inconclusive, and a recent pooled-analysis of 18
prospective studies found no association between andro-
gens and prostate cancer risk [3]. Nevertheless, the prostate
cancer prevention trial’s (PCPT) ﬁnding that ﬁnasteride, a
5a-reductase inhibitor suppressing production of active 5a-
dihydrotestosterone (DHT), signiﬁcantly reduced the risk
of prostate cancer, provides compelling evidence for the
importance of androgens in prostate carcinogenesis [4].
In comparison to androgens, the role of estrogens in
prostate carcinogenesis is more elusive. As men age and
their risk of prostate cancer increases, testosterone con-
centrations decline while estradiol remains stable, resulting
in an elevating ratio of estradiol to testosterone [5–7]. The
temporal coincidence of this shifting hormonal relationship
and prostate cancer risk may suggest a possible relationship
between estrogens and carcinogenesis [8]. This hypothesis
is further supported by ﬁndings in the Noble rat [9] and the
aromatase knockout mice models [10] that androgen plus
estrogen, but not androgen alone, induces prostate malig-
nancy. However, previous observational studies on circu-
lating estrogens and prostate cancer risk have not reported
positive correlations as summarized in pooled- and meta-
analyses [3, 11, 12]. In fact, estrogens have been inversely
linked to prostate cancer risk in at least three prospective
studies [13–15]. More well-designed epidemiologic studies
are warranted to clarify the relationships between estrogens
and prostate cancer risk.
The relationships between estrogens and prostate cancer
risk after ﬁnasteride treatment may differ from those
among men not on the drug, because the intervention alters
the course of prostate carcinogenesis. Moreover, ﬁnasteride
has a direct inﬂuence on estrogen concentrations by sup-
pressing the conversion of testosterone (T) to DHT,
increasing the amount of T available for aromatization to
estrogens [16]. It is unknown whether ﬁnasteride-associ-
ated increase in estrogen levels has any effect on prostate
cancer risk.
Latent prostate cancer is common among older men, and
this undiagnosed disease will cause misclassiﬁcation of
disease status in studies on prostate cancer etiology. This
bias is minimized in the PCPT, because participants were
screened annually and those not diagnosed with cancer
during the trial were recommended for biopsy at the end of
the study. Therefore, the PCPT provides an ideal study
population to reﬁne etiologic risk factors for early stage
prostate cancer. In this nested case–control study, we
investigate the relationships between serum estrone and
estradiol and risk of prostate cancer overall and by Gleason
grade, the effects of ﬁnasteride treatment on serum estro-
gens concentrations, and associations of the changes in
estrogen concentrations due to ﬁnasteride treatment with
prostate cancer risk.
Methods and materials
Study design and population
All data and biospecimens used in this study were previ-
ously collected and stored in the biorepository of the PCPT.
The PCPT was a Phase III double-blinded, placebo-con-
trolled trial, administered through the Southwest Oncology
Group, that tested whether ﬁnasteride could reduce the
period prevalence of prostate cancer during a 7-year
intervention. Details regarding study design and population
characteristics have been described previously [4]. Brieﬂy,
18,882 men aged 55 years or older with a normal digital
rectal examination (DRE), a prostate-speciﬁc antigen
(PSA) level of B 3 ng/ml, and no prior history of prostate
cancer, severe benign prostate hyperplasia, or other clini-
cally signiﬁcant coexisting conditions, were randomized to
receiving ﬁnasteride (5 mg/day) or placebo. Participants
underwent DRE and PSA testing annually, and prostate
biopsy was recommended for participants with an abnor-
mal DRE or a PSA of C 4.0 ng/ml. The PSA level
prompting a biopsy recommendation in the ﬁnasteride
group was adjusted to yield a similar number of biopsy
recommendations in both study groups. After 7 years on
study, all men, including those with a PSA B 4.0 ng/ml
and normal DRE and who were not previously diagnosed
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All biopsies were performed under transrectal ultrasono-
graphic guidance and included a minimum of six cores.
Biopsies were reviewed by both the pathologist at the local
study site and at a central PCPT pathology laboratory to
conﬁrm the diagnosis of adenocarcinoma. Discordant
pathology diagnoses were reviewed by a referee patholo-
gist, and concordance was achieved in all cases [4]. The
Gleason scoring system was used centrally to grade the
tumor. Low-grade prostate cancer was deﬁned as tumors
with Gleason score\7 and high-grade prostate cancer
with Gleason score C 7.
At the termination of the PCPT after 7 years, a total of
1,809 men were biopsy-proven to develop prostate cancer,
and consisted the case pool for this nested case–control
study. Biopsy-negative controls were frequency matched to
cases on age in 5-year increments, treatment arm (ﬁnaste-
ride vs. placebo) and positive family history (ﬁrst degree
relative with prostate cancer). Controls were oversampled
to include all non-whites to increase power for analyses by
race/ethnicity. The ﬁnal sample size for this study, after
accounting for missing estrogen data, was 1,798 cases and
1,798 controls.
Data and biospecimen collection
Following informed consent and enrollment, data on socio-
demographic characteristics, including age, race, educa-
tion, physical activity, smoking, alcohol consumption, and
family history of prostate cancer were collected. Height
and weight were measured at the baseline clinic visit, and
weight was measured annually thereafter. Body mass index
(BMI) was calculated as weight (kg) divided by the square
of height (m
2) and categorized as\25 kg/m
2 (normal),
25–29.9 kg/m
2 (overweight), and C 30 kg/m
2 (obese).
Non-fasting blood samples were collected from all partic-
ipants at the baseline visit and annually thereafter. Detailed
procedures for blood collection, processing, and storage
have been described previously [17]. A portion of the
serum was used for PSA testing and the reminder was
aliquoted and stored at -70C until analysis.
Measurement of serum estrone and estradiol
concentrations
For men in the ﬁnasteride arm, baseline levels were mea-
sured based on serum samples collected approximately
3 months prior to randomization. For the majority of the
men in the placebo arm, to reduce intra-individual vari-
ability and to conserve limited pre-randomization samples,
0.5 ml serum samples collected at baseline and at Year 3
(n = 1,667) was pooled before estrogen analysis. For a
small subset of men without Year 3 samples available,
samples collected at an alternate year were used (n = 180
cases and n = 56 controls at Year 1–7). We tested the
intra-class correlation for serum levels of estrone and
estradiol based on 150 men on the placebo with separate
measurement at baseline and at Year 3, which were 0.62
and 0.74, respectively. For those men, the mean of the two
assays were used in the analysis. There was another subset
of 162 men who were measured based on a single pre-
randomization sample. When prostate cancer was diag-
nosed within 3 years from randomization (n = 201 from
both treatment arms), post-randomization samples col-
lected at an earlier time point before diagnosis was used.
Serum concentrations of estrone and estradiol were deter-
mined by radioimmunoassay (RIA). Before RIA, puriﬁca-
tion steps including an organic solvent extraction and
Celite column partition chromatography were performed to
increase assay sensitivity and speciﬁcity, which are
essential for measurement of the usually low concentra-
tions of estrogens in men [13]. The coefﬁcients of variation
(CV) for estrone and estradiol assays were calculated based
on blind pools of control samples included in the analysis.
Across different pools, the intra-batch CV% ranged from
8.7–19.1% for estrone and 8.6–20.6% for estradiol. The
inter-batch CV% ranged from 9.1–14.6% for estrone and
10.4–13.7% for estradiol. The sensitivities of the estrone
and estradiol RIAs were 10 and 5 pg/ml, respectively.
Statistical analysis
Standard univariate approaches including chi-square test
for categorical variables and t test for continuous variables
were used for comparisons of descriptive characteristics
between cases and controls. Pearson correlation coefﬁ-
cients were used to examine associations between contin-
uous variables. To examine the effects of ﬁnasteride
treatment on circulating estrogen concentrations, the
absolute change as a linear outcome was modeled by
treatment arm (ﬁnasteride vs. placebo) with control for
baseline value and age. The linear regression coefﬁcient
and corresponding p-value were used as indicators for age-
and baseline-adjusted treatment effects. Similar regression
models were used with log-transformed ratio of concen-
trations at follow-up to these at baseline, which after back
transformation are reported as percentage change.
To estimate prostate cancer risk associated with serum
concentrations of estrogens, they were categorized into
quartiles based on their distributions among controls. To
estimate prostate cancer risk associated with changes of
serum estrogen concentrations after ﬁnasteride treatment,
both absolute change and percent change were categorized
into four categories, described as decrease, minimum
change, moderate increase, and large increase, based on
a priori cut-off points derived from examining the
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gorized into quartiles based on the distribution among
controls; however, results were similar and are thus not
presented. Removing potential outliers that fell off three
times of the interquartile range from the median, or were
determined to be physiologically inappropriate, did not
substantially alter the results. Therefore, results based on
all measures including these potential outliers are
presented.
Unconditional logistic regression models were used to
derive odds ratios (ORs) and 95% conﬁdence intervals (CIs)
for overall prostate cancer risk, and polytomous logistic
regression models were used for low-grade (Gleason
score\7) and high-grade (Gleason score C 7) prostate
cancer compared to controls. All of these analyses were
performed separately by treatment groups. Covariates
included in the models were age (continuous), BMI
(continuous), race (white vs. non-white), and sex hormone-
binding globulin (SHBG) (continuous). Additional adjust-
ment for testosterone concentrations was performed for all
models. Potential effect modiﬁcation by testosterone levels,
BMI, race, family history of prostate cancer, diabetes and
cause of cancer diagnosis, i.e., whether cancer was diag-
nosedafteranelevatedPSAorabnormalDRE(for-cause)or
at the end of the trial without cause (not-for-cause), were
tested by including a multiplicative term in the models.
Analyses were performed using SAS 9.0 (SAS Institute,
Cary, NC). All p-values were 2-sided with a signiﬁcance
level of 0.05.
Results
Demographic and lifestyle characteristics of the study
population are given in Table 1. PSA levels at baseline
were signiﬁcantly higher in cases than in controls. The
majority of men were overweight or obese. The proportion
of non-white men in controls was higher than in cases due
to sampling strategy. Case and controls did not differ by
smoking status; but as reported previously [18], cases were
slightly more likely to consume alcohol than controls. Only
a small proportion of men had diabetes at baseline, with a
higher proportion in controls than in cases.
Among men in the placebo group, there were no sig-
niﬁcant associations between baseline estrone or estradiol
levels and overall prostate cancer risk (Table 2). Results
remained similar when stratiﬁed by Gleason grade, with the
exception of a reduced risk of high-grade prostate cancer in
the second quartile of estrone level (OR = 0.57, 95%
CI = 0.36–0.89). When Gleason grade of 8–10 was used as
a deﬁnition of high-grade cancer, the results were similar to
those of Gleason grade of 7–10 (data not shown). There
were no signiﬁcant effect modiﬁcations by testosterone
levels, BMI, race, diabetes, family history of prostate
cancer, or cause of cancer diagnosis (data not shown).
Associations between baseline levels of estrone and
estradiol among men in the ﬁnasteride group are shown in
Table 3. Compared to men in the lowest quartile of estrone
levels, those in the highest quartiles had 43% increased risk
of low-grade prostate cancer risk. Similarly, men in the
highest quartile of estradiol levels had 34% increased risk
of low-grade cancer risk. Revising the deﬁnition of high-
grade cancer by Gleason grade 8–10 did not substantially
change the results (data not shown). The increased risk
became slightly stronger after control for testosterone, and
were strongest among those without a positive family
history of prostate cancer (for estrone, OR = 1.77, 95%
CI = 1.18–2.66, P for trend\0.01; for estradiol,
OR = 1.79, 95% CI = 1.17–2.75, P for trend = 0.01).
Nevertheless, interaction testings for testosterone, BMI,
race, diabetes, family history of prostate cancer or cause of
cancer diagnosis showed no effect modiﬁcation (data not
shown).
Table 4 summarizes the effects of ﬁnasteride treatment
on serum estrogen concentrations. Overall, concentrations
of estrogens at year 3 of the trial were increased signiﬁ-
cantly in the ﬁnasteride but not in the placebo group. These
effects were similar after stratiﬁcation for case–control
status or tumor grade, with the exception of a signiﬁcant
decrease in placebo men who developed low-grade cancer.
After adjustment for age and baseline estrogen concentra-
tions, overall treatment effects were ?11.9% for estrone
and ?9% for estradiol, and did not differ by case–control
status or grade; although not all tests reached statistical
signiﬁcance among low-grade and high-grade cases due to
limited sample size.
There were no signiﬁcant associations of cancer risk in
the ﬁnasteride group with either the absolute or the percent
change in estrone or estradiol following treatment, with an
exception of an inverse trend between percentage increase
in estradiol concentrations and risk of low-grade cancer
(Table 5). However, the same inverse association was not
found with the absolute change and the odds ratio con-
trasting the highest to lowest quartile was not statistically
signiﬁcant.
Discussion
Among men randomized to the placebo group in the PCPT,
there were no associations of baseline levels of estrogens
with prostate cancer risk. Among those randomized to the
ﬁnasteride group, high estrogen levels at baseline were
associated with a moderately increased risk of low-grade
but not high-grade prostate cancer. Serum concentrations
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ﬁnasteride treatment; however, this increase was not
associated with prostate cancer risk.
Previous epidemiologic studies provide inconsistent
results on the relationships between circulating levels of
estrogens and prostate cancer risk. While most studies
Table 1 Demographic and lifestyle characteristics of cases and controls in the PCPT
All (n = 3,596) Control (n = 1,798) Case (n = 1,798) p-value
a
Mean ± SD Mean ± SD Mean ± SD
Age at baseline, years 63.6 ± 5.5 63.6 ± 5.5 63.7 ± 5.5 0.61
Baseline PSA, ng/ml 1.4 ± 0.8 1.2 ± 0.7 1.6 ± 0.7 \0.01
BMI at baseline, kg/m
2 27.5 ± 4.0 27.6 ± 4.0 27.4 ± 4.0 0.12
N (%)
b N (%)
b N (%)
b
Age at baseline, year
c 1.00
55–59 956 (26.6) 478 (26.6) 478 (26.6)
60–64 1,166 (32.4) 583 (32.4) 583 (32.4)
65–69 886 (24.6) 443 (24.6) 443 (24.6)
70? 588 (16.4) 294 (16.4) 294 (16.4)
BMI 0.08
Normal (\25 kg/m
2) 941 (26.4) 444 (24.9) 497 (27.9)
Overweight (25–29.9 kg/m
2) 1,854 (52.0) 942 (52.9) 912 (51.1)
Obese (C 30 kg/m
2) 768 (21.6) 394 (22.1) 374 (21.0)
Race
d \0.01
Non-hispanic white 3,098 (86.2) 1,429 (79.5) 1,669 (92.8)
Non-hispanic black 254 (7.1) 171 (9.5) 83 (4.6)
Hispanic 177 (4.9) 140 (7.8) 37 (2.1)
Other 67 (1.9) 58 (3.2) 9 (0.5)
Family history
c 0.94
No 2,832 (78.8) 1,417 (78.8) 1,415 (78.7)
Yes 764 (21.2) 381 (21.2) 383 (21.3)
Smoking status 0.51
Never smoker 1,254 (34.9) 615 (34.2) 639 (35.5)
Current smoker 263 (7.3) 139 (7.7) 124 (6.9)
Former smoker 2,079 (57.8) 1,044 (58.1) 1,035 (57.6)
Alcohol consumption 0.04
\1 drink/week 1,508 (44.8) 800 (46.6) 708 (42.9)
1–6 drinks/week 909 (27.0) 457 (26.6) 452 (27.4)
7–13 drinks/week 505 (15.0) 241 (14.0) 264 (16.0)
14 ? drinks/week 444 (13.2) 219 (12.8) 225 (13.6)
Diabetes \0.01
No 3,378 (94.0) 1,664 (92.6) 1,714 (95.3)
Yes 217 (6.0) 133 (7.4) 84 (4.7)
Treatment arm
c 0.95
Placebo 2,072 (57.6) 1,035 (57.6) 1,037 (57.7)
Finasteride 1,524 (42.4) 763 (42.4) 761 (42.3)
Gleason score –
\7 – – 1,230 (71.4)
C7 – – 493 (28.6)
a p-values are based on student t test for continuous variables and chi-square test for unordered categorical variables between cases and controls.
For ordered categorical variables, ordinal numbers were assigned to levels and then treated as continuous variables to give trend p-values
b For speciﬁc variables, men with missing data are not shown. The count and percentage are based on those with known values
c Cases and controls are matched on age, family history, and treatment arms
d Controls are oversampled to include all non-White men. SD standard deviation
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123found null associations [19–26], which may have driven a
same conclusion in several meta- and pooled-analysis [3,
11, 12], three studies showed reduced risk among those
with high estrogen levels [13–15]. In contrast, a recent
case-cohort study with 275 prostate cancer cases reported
an increased risk among those in the highest 3 quartiles of
estrone levels, but there were no associations with estradiol
levels [27]. This inconsistency may be due to the balance
of the opposing effects of estrogens in the prostate, and the
lack of assessment of estrogen receptor activity in the
prostate gland. It has been hypothesized that estrogens may
play dual and opposing roles in prostatic homeostasis and
carcinogenesis [28]. Estrogens can cause abnormal prolif-
eration, inﬂammation, and prostate malignancy, mediated
by estrogen receptor a (ER-a), but they may also confer
important beneﬁcial effects, including anti-proliferation,
anti-inﬂammation, and anti-carcinogenesis, mediated by
ER-b. The balance between activities of the two ER sub-
types may dictate prostatic responses to estrogens [29]. The
exact mechanisms for coordination between these opposing
effects of estrogens and disruption during prostate carci-
nogenesis are unclear.
Among men in the ﬁnasteride group, high estrogen
levels at baseline were associated with an increased risk of
low-grade prostate cancer. It is possible that ﬁnasteride
could modify the relationships between estrogens and
prostate cancer risk, although a mechanism for this is not
obvious. Alternatively, estrogen may modify the efﬁcacy
of ﬁnasteride for prevention of low-grade prostate cancer.
Because of the nested case–control design, we could not
distinguish these possibilities. This issue needs to be
investigated in the entire PCPT cohort and would require
Table 4 Changes of serum estrone and estradiol concentrations between baseline and follow-up in the PCPT
Finasteride arm
a Placebo arm
a Adjusted treatment effect
Baseline Follow-up Change Baseline Follow-up Change Absolute changes
b Percent increase
c
Mean ± SD Mean ± SD Mean ± SE Mean ± SD Mean ± SD Mean ± SE b ± SE p-value % (95% CI) p-value
All
N 1,497 1,496 1,490 150 150 150
Estrone, pg/ml 46.6 ± 15.7 51.2 ± 16.9 4.6 ± 0.4 48.5 ± 16.6 46.6 ± 14.7 -1.9 ± 1.1 5.8 ± 1.2 \0.01 11.9 (7.2–16.9) \0.01
N 1,507 1,506 1,500 150 150 150
Estradiol, pg/ml 34.5 ± 11.5 36.9 ± 12.2 2.5 ± 0.3 32.5 ± 9.3 32.5 ± 9.1 -0.1 ± 0.5 3.4 ± 0.9 \0.01 9.0 (4.6–13.6) \0.01
Controls
N 755 753 750 110 110 110
Estrone, pg/ml 46.1 ± 15.7 50.9 ± 17.0 4.7 ± 0.6 48.7 ± 17.5 47.7 ± 15.1 -1.0 ± 1.3 4.7 ± 1.4 \0.01 9.3 (3.8–15.0) \0.01
N 757 756 752 110 110 110
Estradiol, pg/ml 34.6 ± 12.7 36.6 ± 11.8 2.0 ± 0.4 32.1 ± 9.7 32.0 ± 9.1 -0.1 ± 0.6 3.3 ± 1.0 \0.01 8.4 (3.2–13.8) \0.01
Cases
N 743 743 740 40 40 40
Estrone, pg/ml 47.0 ± 15.6 51.5 ± 16.8 4.5 ± 0.6 48.1 ± 14.0 43.7 ± 13.1 -4.5 ± 1.6 8.6 ± 2.2 \0.01 19.4 (9.9–29.7) \0.01
N 750 750 748 40 40 40
Estradiol, pg/ml 34.4 ± 10.3 37.3 ± 12.7 2.9 ± 0.4 33.6 ± 8.4 33.6 ± 9.2 0.03 ± 0.9 3.2 ± 1.7 0.06 9.2 (1.0–18.0) 0.03
Low-grade cases
N 443 442 441 29 29 29
Estrone, pg/ml 47.2 ± 15.2 51.6 ± 17.2 4.7 ± 0.7 50.0 ± 14.4 43.9 ± 13.6 -6.1 ± 2.0 9.8 ± 2.6 \0.01 21.6 (10.3–33.9) \0.01
N 447 445 445 29 29 29
Estradiol, pg/ml 34.8 ± 9.8 37.4 ± 13.1 2.6 ± 0.5 33.9 ± 9.0 33.9 ± 9.8 0.1 ± 1.0 2.8 ± 2.1 0.18 7.4 (-1.9–17.7) 0.12
High-grade cases
N 269 271 269 11 11 11
Estrone, pg/ml 46.6 ± 16.3 51.4 ± 16.2 4.9 ± 16.8 43.3 ± 12.1 43.0 ± 12.1 -0.3 ± 2.0 6.8 ± 4.4 0.12 15.6 (-1.3–35.4) 0.07
N 272 274 272 11 11 11
Estradiol, pg/ml 33.7 ± 10.8 37.5 ± 12.1 3.8 ± 10.5 32.8 ± 7.0 32.7 ± 7.7 -0.1 ± 2.2 4.4 ± 3.0 0.14 13.3 (-2.6–31.8) 0.11
a Estrogen concentrations at baseline and at follow-up of approximately three years after on the study are presented in raw values. The changes are calculated as
values at follow-up minus values at baseline
b Treatment effect is calculated as regression coefﬁcient (b) of treatment arm (ﬁnasteride vs. placebo) in the linear regression model with absolute changes of
estrogen concentrations as the dependent variable. The p-values compare the mean changes in estrogen concentrations between the treatment arms, with adjustment
for baseline concentrations and age
c Treatment effect is calculated as regression coefﬁcient of treatment arm in the linear regression model with log-transformed ratio of follow-up to baseline values
as the dependent variable. The percent increase presented in the table is derived by back-transforming the regression coefﬁcient. SD standard deviation, SE standard
error
1128 Cancer Causes Control (2011) 22:1121–1131
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123measurement of serum estrogen levels from all partici-
pants, which is currently available only from cases and
controls included in this nested study. We examined the
linear correlations of baseline concentrations of estrone and
estradiol with the change of 5a-androstane-3a,17b-diol
glucuronide (3a-diol G), a metabolite of DHT that reﬂects
concentrations of intra-prostatic DHT and thus indirectly
measures the ﬁnasteride treatment effect, following ﬁnas-
teride treatment. There were signiﬁcant inverse associa-
tions between baseline estrogens and change in 3a–dG
(r =- 0.09 for estrone and r =- 0.11 for estradiol, both
P\0.001). However, because the strength of these cor-
relations was weak, it does not support a strong or direct
effect of estrogens on ﬁnasteride treatment efﬁcacy. It is
also possible that the observed increased risk was biased by
factors potentially related to estrogen. Estrogen concen-
trations are positively associated with obesity; however, the
effects of ﬁnasteride on cancer risk did not differ by obesity
[30]. The possibility that whether other factors such as diet
or physical activity modify the effects of ﬁnasteride treat-
ment have not yet been evaluated.
Baseline estrogens may have been associated with high
PSA and therefore bias in cancer detection; but there were
no associations of estrogen concentrations with baseline
PSA (Spearman correlation coefﬁcient ranges from -0.08
to 0.05 in cases or controls from the placebo or ﬁnasteride
arm, with or without adjustment for age and BMI). Lastly,
we could not rule out the possibility that these ﬁndings
were due to chance alone. However, the hypotheses were
all a priori and the associations were observed consistently
for estrone and estradiol with signiﬁcant trends, which
lower the likelihood of chance ﬁndings. Overall, we cannot
explain the ﬁndings of a positive association of baseline
estrogens with cancer risk in ﬁnasteride-treated men, which
warrants further research.
We had hypothesized that the magnitudes of increases in
estrogens following ﬁnasteride treatment may have
increased prostate cancer risk. However, with only a single
exception, neither the changes in estrogens nor the post-
treatment estrogen concentrations were associated with
cancer risk. There was a suggestive trend of increased risk
of low-grade cancer with percentage increase in estrone;
however, because the odds ratio contrasting extreme
quartiles was not statistically signiﬁcant and there was no
association of absolute change with risk, we deem this as a
chance ﬁnding. Moreover, the magnitude of changes in
estrogens in the ﬁnasteride arm following treatment were
modest (mean change, 4.6 pg/ml for estrone and 2.5 pg/ml
for estradiol), compared to the inter-quartile differences in
at baseline (for estrone, Q1 B 35.5 pg/ml, Q4[53.2 pg/
ml; for estradiol, Q1 B 26.7 pg/ml, Q4[39.4 pg/ml).
Thus, it is unlikely that changes in estrogens of these small
magnitudes have physiological or clinical signiﬁcance.
The study beneﬁts from vigorous annual screening by
DRE and PSA test, and an end-of-study biopsy offered to
all men who were cancer-free at the exit of the study. These
measures greatly reduced the likelihood of undiagnosed
prostate cancer in the control group and minimize mis-
classiﬁcation. Moreover, the PCPT adapted a centralized
and standardized approach for cancer grading, minimizing
misclassiﬁcation. Other strengths include puriﬁcation steps
before RIA for estrogen measurement and a large sample
size nested within a completed multi-center trial. However,
several limitations should also be considered in this study.
First, non-fasting blood samples were collected at different
daily times and thus variations in estrogen levels
throughout the day could not be controlled for; however,
these variations were not likely to be systematically dif-
ferent between cases and controls [17]. Second, circulating
estrogens may not reﬂect intraprostatic levels [31]. Local
expression of aromatase and production of estrogen in the
prostate further complicates the relevance of circulating
levels to prostate cancer etiology [32]. However, this issue
is not speciﬁc to our study but common to all studies
examining circulating biomarkers, and measurement of
intra-prostatic hormone levels is currently not feasible for
large-scale epidemiologic studies.
In summary, we found no evidence for an association of
estrogen levels with prostate cancer risk among men not on
ﬁnasteride. Among those taking ﬁnasteride, there may be a
positive association of pretreatment estrogen concentra-
tions and risk of low-grade prostate cancer; however, we
know of no mechanisms that could explain such an asso-
ciation. These results add to a body of previous published
studies ﬁnding no associations of circulating estrogen
concentrations with prostate cancer risk. The moderate
increase in risk of low-grade prostate cancer associated
with high baseline levels of estrogen among men taking
ﬁnasteride warrants further investigation.
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